{"gene":"ADAMTS7","run_date":"2026-06-09T22:02:41","timeline":{"discoveries":[{"year":1999,"finding":"ADAMTS7 (ADAM-TS7) was identified as a novel zinc metalloprotease with a domain organization comprising a preproregion, a reprolysin-type catalytic domain, a disintegrin-like domain, a thrombospondin type-1 (TS) module, a cysteine-rich domain, a spacer domain, and a C-terminal TS module, placing it in the ADAM-TS family of reprolysin-like metalloproteases.","method":"Primary structure determination, genomic distribution analysis, expression profiling during mouse embryogenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — foundational structural characterization with cloning and domain architecture, replicated across family members in same study","pmids":["10464288"],"is_preprint":false},{"year":2004,"finding":"ADAMTS7B, the full-length product of the ADAMTS7 gene, is a proteoglycan modified by chondroitin sulfate attachment within a unique mucin domain, is retained near the cell surface via interactions involving the ancillary domain and prodomain, undergoes furin-dependent multistep prodomain removal (with final cleavage at the cell surface after Arg220), and is an active metalloproteinase capable of cleaving alpha-2-macroglobulin but does not cleave versican or aggrecan.","method":"Protein characterization, glycosaminoglycan analysis, furin inhibition assay, in vitro cleavage assay, subcellular localization studies in HEK293F cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (biochemical characterization, mutagenesis-equivalent inhibitor studies, cleavage assays) in a single rigorous study establishing structure-function","pmids":["15192113"],"is_preprint":false},{"year":2006,"finding":"ADAMTS-7 directly binds to and degrades cartilage oligomeric matrix protein (COMP); binding is mediated by the EGF repeat domain of COMP and the four C-terminal TSP motifs of ADAMTS-7; the recombinant catalytic domain and intact ADAMTS-7 cleave COMP in vitro in a Zn2+- and pH-dependent manner (optimal pH 7.5–9.5).","method":"Yeast two-hybrid screen, in vitro GST pull-down, co-immunoprecipitation from native articular cartilage, in vitro digestion assay, domain-mapping experiments","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with domain mapping, yeast two-hybrid plus co-IP in native tissue, multiple orthogonal methods","pmids":["16585064"],"is_preprint":false},{"year":2008,"finding":"ADAMTS-7 cleaves alpha-2-macroglobulin (α2M) in vitro, generating 180- and 105-kDa cleavage products; α2M in turn inhibits ADAMTS-7-mediated COMP degradation in a concentration-dependent manner, representing the first identified endogenous inhibitor of ADAMTS-7.","method":"In vitro digestion assay, siRNA knockdown in human chondrocytes, blocking antibodies in cartilage explants","journal":"Osteoarthritis and cartilage","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro cleavage assay with functional inhibition demonstrated, corroborated by siRNA and antibody approaches","pmids":["18485748"],"is_preprint":false},{"year":2009,"finding":"ADAMTS-7 mediates vascular smooth muscle cell (VSMC) migration and neointima formation; ADAMTS-7 protein accumulates in neointima after balloon injury; TNF-α and PDGF-BB induce ADAMTS-7 expression; ADAMTS-7 facilitates VSMC migration through degradation of COMP, its vascular ECM substrate; COMP replenishment circumvents the pro-migratory effect.","method":"Rat carotid artery balloon injury model, adenovirus overexpression, siRNA knockdown in vivo and in vitro, VSMC migration/invasion assays, immunohistochemistry","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain- and loss-of-function in vivo with substrate rescue experiment, multiple orthogonal methods, replicated in vitro and in vivo","pmids":["19168437"],"is_preprint":false},{"year":2009,"finding":"ADAMTS-7 is a direct transcriptional target of PTHrP signaling in chondrocytes; it inhibits chondrocyte differentiation and endochondral bone formation in a proteolytic activity-dependent manner; the cysteine-rich domain is required for ECM interaction; the C-terminal four TSP motifs are required for full proteolytic activity; ADAMTS-7 associates with and proteolytically inactivates GEP (granulin-epithelin precursor), acting as a GEP convertase to neutralize GEP-stimulated endochondral bone formation.","method":"Transgenic mice, PTHrP knockout mice, ADAMTS-7 overexpression/knockdown, reporter gene assay, domain-deletion constructs, in vitro GEP cleavage assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vivo genetic models with mechanistic rescue, in vitro enzymatic cleavage, domain-mapping, epistasis with PTHrP pathway","pmids":["19487464"],"is_preprint":false},{"year":2010,"finding":"Granulin-epithelin precursor (GEP) directly binds ADAMTS-7 via its C-terminal four TSP motifs (ADAMTS-7 side) and each granulin unit (GEP side); GEP co-localizes with ADAMTS-7 on the chondrocyte cell surface; GEP inhibits ADAMTS-7-mediated COMP degradation through competitive inhibition via direct protein-protein interactions and by suppressing TNF-α-induced ADAMTS-7 expression.","method":"Yeast two-hybrid, GST pull-down, co-immunoprecipitation, immunofluorescence co-localization, in vitro digestion assay, domain-mapping","journal":"Arthritis and rheumatism","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal binding methods plus functional enzymatic inhibition, domain-level mapping","pmids":["20506400"],"is_preprint":false},{"year":2013,"finding":"A non-synonymous SNP rs3825807 (Ser-to-Pro substitution) in the ADAMTS7 prodomain reduces prodomain cleavage/maturation of the protease in VSMCs, resulting in less cleaved thrombospondin-5 (COMP/TSP-5) in conditioned media and reduced VSMC migratory ability; the protective G allele is associated with reduced ADAMTS7 function.","method":"Genotyped VSMC conditioned media analysis, prodomain cleavage assays, VSMC migration assays in cells stratified by genotype","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — biochemical cleavage assay linking SNP to altered prodomain processing and substrate cleavage, functional migration readout, multiple methods in one study","pmids":["23415669"],"is_preprint":false},{"year":2013,"finding":"ADAMTS-7 and TNF-α form a positive feedback loop in osteoarthritis: TNF-α induces ADAMTS-7 expression via NF-κB signaling, while ADAMTS-7 overexpression upregulates TNF-α and metalloproteinases; cartilage-specific ADAMTS-7 overexpression leads to chondrodysplasia and spontaneous OA-like phenotype; knockdown attenuates OA progression.","method":"Cartilage-specific ADAMTS-7 transgenic mice, siRNA knockdown mice, surgically-induced OA model, NF-κB reporter gene assay, immunohistochemistry","journal":"Annals of the rheumatic diseases","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gain- and loss-of-function genetic models, reporter assay establishing NF-κB pathway, replicated across multiple OA models","pmids":["23928557"],"is_preprint":false},{"year":2015,"finding":"ADAMTS-7 inhibits re-endothelialization of injured arteries by degrading thrombospondin-1 (TSP-1); ADAMTS-7 directly associates with TSP-1 via its C-terminus and degrades TSP-1 in vivo and in vitro; Adamts7-/- mice show greatly promoted re-endothelialization and reduced neointima formation; the inhibitory effect of ADAMTS-7 on endothelium recovery is abolished in Tsp1-/- mice (but not in COMP-/- mice), demonstrating TSP-1 as the relevant substrate for this effect.","method":"Adamts7-/- and Tsp1-/- mouse wire injury models, Evans blue staining, label-free LC-MS/MS secretome analysis, in vitro co-association and degradation assays, endothelial cell proliferation/migration assays","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo (double KO rescue), in vitro biochemical confirmation, mass spectrometry substrate discovery, multiple orthogonal methods","pmids":["25712208"],"is_preprint":false},{"year":2015,"finding":"Adamts7 knockout in hyperlipidemic mouse models (Ldlr-/- and Apoe-/-) significantly reduces atherosclerotic lesion formation and neointimal formation; ADAMTS7 is proatherogenic; ADAMTS7 co-localizes with smooth muscle cell markers in human CAD lesions and localizes to the cytoplasm and cell membrane in cultured VSMCs, co-localizing with podosome markers; primary Adamts7-/- VSMCs show reduced migration under TNF-α stimulation.","method":"Whole-body knockout mice crossed to hyperlipidemic backgrounds, femoral wire injury model, VSMC migration assays, subcellular localization studies, immunohistochemistry of human lesions","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — first in vivo genetic validation in two atherosclerosis models, human tissue corroboration, subcellular localization with functional correlate","pmids":["25712206"],"is_preprint":false},{"year":2019,"finding":"TAILS unbiased substrate profiling identified LTBP3 and LTBP4 as ADAMTS7 substrates; ADAMTS7 cleaves LTBP4 at multiple sites in an N-terminal linker region connecting fibulin-5/tropoelastin and fibrillin-1-binding regions; ADAMTS7 undergoes autolysis at Glu729-Val730 and Glu732-Ala733 in the Spacer domain; TIMP-4 is the most potent endogenous inhibitor of ADAMTS7 (compared to TIMP-1, -2, -3).","method":"TAILS proteomic substrate analysis of human fibroblast secretome, N-terminal sequencing, Western blotting, in vitro cleavage assay with purified ADAMTS7 and recombinant LTBP4, metalloprotease inhibitor panel","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — unbiased proteomics plus in vitro reconstitution with purified components and N-terminal sequencing confirmation, single lab with multiple orthogonal methods","pmids":["30926607"],"is_preprint":false},{"year":2019,"finding":"Wnt/β-catenin signaling (induced by IL-1β or Wnt7B) drives ADAMTS-7 expression in osteoarthritis synovial fibroblasts, and ADAMTS-7 from synovial fibroblasts contributes to COMP degradation in cartilage; blockade of Wnt signaling by DKK1 reduces ADAMTS-7 expression and COMP degradation.","method":"OA synovial fibroblast cultures, ERK inhibition, DKK1 Wnt pathway blockade, COMP degradation assays","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, pharmacological pathway inhibition with functional readout but no direct epistasis","pmids":["30903650"],"is_preprint":false},{"year":2022,"finding":"TAILS in vascular smooth muscle and endothelial cells identified 24 unique cleavage sites from 16 protein substrates of ADAMTS7; EFEMP1 (Fibulin-3) was identified as an ADAMTS7 substrate with a preferred cleavage site at amino acids 123–124, validated by in vitro binary cleavage assay with purified EFEMP1.","method":"TAILS with ADAMTS7 WT vs. catalytic mutant (E373Q) adenovirus expression in VSMCs and ECs, in vitro binary cleavage assay with purified EFEMP1","journal":"Molecular & cellular proteomics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — unbiased proteomics with catalytic dead mutant negative control plus in vitro reconstitution with purified substrate, multiple independent TAILS experiments","pmids":["35283288"],"is_preprint":false},{"year":2022,"finding":"Vaccination with a peptide (ATS7vac) derived from ADAMTS7 generates specific antibodies that inhibit ADAMTS-7-mediated COMP and TSP-1 degradation, suppress VSMC migration, and promote re-endothelialization, confirming COMP and TSP-1 degradation as the mechanistic basis of ADAMTS7 proatherogenicity.","method":"Murine carotid artery ligation, wire injury, atherosclerosis models (ApoE-/- and LDLR-/-), swine coronary stent model, in vitro substrate cleavage assays with vaccination-derived antibodies","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple animal models with mechanistic readout, in vitro substrate cleavage confirmation, translational validation in pigs","pmids":["36562301"],"is_preprint":false},{"year":2023,"finding":"ADAMTS-7 binds to and degrades TIMP-1 via its catalytic domain; ADAMTS-7-mediated TIMP-1 degradation reduces TIMP-1's inhibitory capacity on MMP-9, leading to increased MMP-9 activity and collagen degradation in atherosclerotic plaques; Adamts7-/- atherosclerotic aortas show higher TIMP-1 levels and greater collagen content.","method":"Mass spectrometry of atherosclerotic plaques from Apoe-/- vs. Apoe-/-Adamts7-/- mice, co-immunoprecipitation, FRET-based protein-protein interaction assay, in vitro degradation assay, Picrosirius red collagen staining","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — unbiased mass spectrometry identification followed by co-IP, FRET PPI assay, and in vitro degradation reconstitution with functional downstream MMP-9 readout, multiple orthogonal methods","pmids":["37675562"],"is_preprint":false},{"year":2023,"finding":"ADAMTS7 binds to complement factor H (CFH) at CCP domains 1–4 and degrades the CCP 1–7 domain through multiple cleavages; ADAMTS7 deficiency alleviates complement activation and related renal pathologies in lupus nephritis and renal ischemia-reperfusion injury models; adeno-associated virus-mediated CFH silencing abolished the protective effects of ADAMTS7 knockout, establishing the ADAMTS7→CFH degradation→complement activation axis.","method":"Unbiased interactome of lupus mice kidneys, in vitro cleavage assay, Adamts7-/- mouse models of SLE and renal I/R injury, AAV-mediated CFH silencing rescue experiment","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro cleavage reconstitution, domain mapping, genetic epistasis rescue in vivo with AAV-CFH silencing, multiple orthogonal approaches","pmids":["36735376"],"is_preprint":false},{"year":2018,"finding":"ADAMTS7 and ADAMTS12 together protect against heterotopic ossification (HO) in hindlimb tendons, menisci, and ligaments; Adamts7-/-Adamts12-/- double-knockout mice (but not single knockouts) develop progressive HO, accompanied by abnormal collagen fibrils and reduced levels of the SLRPs biglycan, fibromodulin, and decorin, implicating these proteoglycans as downstream mediators.","method":"Single and double knockout mouse models, histology, collagen fibril analysis by electron microscopy, SLRP protein level measurements","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via single vs. double knockout establishing functional redundancy, with mechanistic substrate/downstream effector identification","pmids":["29618652"],"is_preprint":false},{"year":2024,"finding":"ADAMTS7 promotes smooth muscle cell (SMC) foam cell formation and atherosclerosis via an AP-1/PU.1/CD36 regulatory axis: ADAMTS7 expression increases chromatin accessibility at AP-1-enriched regions, upregulating PU.1 (a myeloid transcription factor), which in turn increases CD36 expression and oxidized LDL uptake by SMCs; SMC-specific and EC-specific Adamts7 conditional transgenic mice both show increased atherosclerosis, whereas conditional knockout in either cell type does not reduce atherosclerosis.","method":"SMC- and EC-specific conditional KO and transgenic mice, RNA-seq, ATAC-seq with motif analysis, oxLDL uptake assays, single-cell RNA-seq of human carotid atherosclerosis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic models, multi-omics (RNA-seq, ATAC-seq), functional assay, human tissue validation, multiple orthogonal methods","pmids":["41609669"],"is_preprint":false},{"year":2024,"finding":"BAY-9835, the first orally bioavailable selective ADAMTS7 inhibitor, was designed using X-ray co-crystal structure of the ADAMTS7 catalytic domain to exploit amino acid differences between ADAMTS7 and MMP12 binding sites; the compound selectively inhibits the ADAMTS7 catalytic zinc-containing metalloproteinase domain.","method":"X-ray crystallography co-crystal structure, in silico homology modeling, medicinal chemistry optimization, in vitro enzymatic inhibition assays","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure-based design with in vitro enzymatic validation, first structural data on ADAMTS7 catalytic domain-inhibitor interaction","pmids":["38348661"],"is_preprint":false},{"year":2021,"finding":"A fluorogenic FRET substrate (ATS7FP7) was developed for ADAMTS7 activity measurement; TIMP-4 shows the highest inhibitory potency among TIMPs for ADAMTS7 (confirmed with both fluorogenic substrate and SDS-PAGE assay using LTBP4S-A), supporting TIMP-4 as the primary physiological inhibitor.","method":"Fluorogenic FRET substrate assay development, inhibition constant measurements for TIMP-1/-2/-3/-4 and hydroxamate inhibitors","journal":"Journal of enzyme inhibition and medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro enzymatic assay with purified components, single lab, but confirms prior TIMP-4 finding with new orthogonal method","pmids":["34587841"],"is_preprint":false},{"year":2015,"finding":"ADAMTS-7 promotes VSMC proliferation in vitro and in vivo; adenoviral ADAMTS-7 overexpression increases the percentage of PCNA-positive cells in intima and media after injury; siRNA knockdown reduces intimal VSMC replication; [3H]-thymidine incorporation assay shows 61% enhanced and 23% reduced replication with overexpression and knockdown respectively.","method":"Rat carotid artery injury model with adenoviral delivery, perivascular siRNA administration, [3H]-thymidine incorporation assay in primary VSMCs, PCNA immunostaining","journal":"Science China. Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in vivo and in vitro with quantitative proliferation readouts, single lab","pmids":["25921940"],"is_preprint":false},{"year":2020,"finding":"ADAMTS7 promotes angiogenesis in endothelial cells via TSP-1 degradation: ADAMTS7 knockdown attenuates EC migration and tube formation; ADAMTS7-Ser214 overexpression increases these; proteomics shows inverse TSP-1 levels in conditioned media correlating with ADAMTS7 status; the pro-angiogenic effect is abolished by a TSP-1 blocking antibody; the Ser214Pro substitution (CAD-protective variant) reduces TSP-1 degrading activity.","method":"ADAMTS7 knockdown/overexpression in ECs, proteomics of conditioned media, TSP-1 cleavage assay, tube formation and migration assays, TSP-1 blocking antibody rescue","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (proteomics, functional rescue, cleavage assay), single lab","pmids":["32005000"],"is_preprint":false},{"year":2025,"finding":"ADAMTS7 and ADAMTS12 are co-expressed in heart valves and each compensates for loss of the other by upregulation; Adamts7-/-Adamts12-/- double knockout mice develop myxomatous aortic valve degeneration with ECM substrate accumulation including periostin; TAILS identified shared and distinct ECM substrates/cleavage sites for each protease; TGFβ signaling was increased in mutant valves.","method":"Adamts7-/-Adamts12-/- double knockout mice, Doppler echocardiography, N-terminomics TAILS from secretome libraries, immunostaining, TGFβ pathway analysis","journal":"Journal of molecular and cellular cardiology plus","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in double KO with compensatory upregulation demonstrated, substrate identification by TAILS, in vivo functional cardiac phenotype","pmids":["40115634"],"is_preprint":false},{"year":2026,"finding":"Cigarette smoke exposure upregulates vascular ADAMTS7 expression via CCL17/CCR4 signaling: cigarette smoke induces CCL17 in lungs and plasma; recombinant CCL17 upregulates ADAMTS7 in VSMCs; CCR4 silencing blocks this upregulation; conditioned media from CCL17-stimulated ADAMTS7-deficient VSMCs shows reduced inflammatory cytokine release by endothelial cells and reduced monocyte-to-EC adhesion; in Apoe-/- mice, smoking-induced plaque inflammation is blunted in Apoe-/-Adamts7-/- mice.","method":"Murine cigarette smoke exposure model, bulk RNA-seq of lung, recombinant CCL17 treatment of VSMCs, CCR4 siRNA knockdown, conditioned media EC activation assay, Apoe-/-Adamts7-/- double KO atherosclerosis model","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — preprint, multiple orthogonal methods including genetic KO epistasis and in vitro pathway validation, single lab","pmids":[],"is_preprint":true},{"year":2024,"finding":"The rs4887091 variant within the ADAMTS7 CAD GWAS locus alters a CTCF binding site and modulates function of a super chromatin interactome in coronary artery smooth muscle cells, linking the disease variant to ADAMTS7 gene regulation through 3D chromatin conformation.","method":"Single-nucleus gene expression and chromatin accessibility profiling (snRNA-seq + snATAC-seq) from 44 human coronary arteries, caQTL mapping, Hi-C chromatin conformation capture","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 4 / Weak — preprint, computational/epigenomic mapping without direct functional validation of ADAMTS7 mechanism","pmids":[],"is_preprint":true},{"year":2026,"finding":"Pharmacological inhibition of ADAMTS7 with BAY-9835 improves left ventricular systolic function and reduces infarct size after AMI in mice; transcriptomic analysis identified the NF-κB/pyroptosis pathway as a downstream mechanism; BAY-9835 inhibits P65 phosphorylation and pyroptosis marker expression; NF-κB activation abolishes BAY-9835 protection.","method":"LAD ligation AMI mouse model, oxygen-glucose deprivation in AC16 cardiomyocytes, transcriptomic analysis, NF-κB pathway pharmacological activation/inhibition, echocardiography","journal":"Toxicology and applied pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological inhibition with functional readout and transcriptomic mechanism, single lab, rescue experiment with NF-κB activator","pmids":["42061659"],"is_preprint":false},{"year":2026,"finding":"In a high-fat diet mouse model, ADAMTS-7 promotes MMP-9 activation in cerebral vessels; ADAMTS-7 shRNA knockdown attenuates HFD-induced MMP-9 activity, reduced middle cerebral arterial diameter, and worsened neurological outcomes after MCAO; ADAMTS-7 is expressed in neurons, astrocytes, oligodendrocytes, and blood vessels in the brain.","method":"HFD mouse model, MCAO, lentiviral shRNA knockdown, Western blotting, immunostaining, cerebral vascular casting","journal":"CNS neuroscience & therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — knockdown with functional readout establishing ADAMTS7→MMP-9 axis in brain vasculature, single lab, single method per endpoint","pmids":["41968389"],"is_preprint":false}],"current_model":"ADAMTS7 is a secreted zinc metalloprotease-proteoglycan that promotes vascular disease by degrading multiple extracellular matrix substrates—principally COMP (inhibiting VSMC migration and maintaining contractile phenotype), thrombospondin-1 (inhibiting re-endothelialization), LTBP4 (potentially affecting elastogenesis), TIMP-1 (disinhibiting MMP-9), and complement factor H (potentiating complement activation)—while in smooth muscle cells it also drives a non-proteolytic AP-1/PU.1/CD36 transcriptional axis that promotes foam cell formation; its prodomain is removed by furin at the cell surface, TIMP-4 is its primary endogenous inhibitor, and its expression is induced by TNF-α, PTHrP, IL-17A, and cigarette smoke-derived CCL17 via NF-κB and CCR4 signaling."},"narrative":{"mechanistic_narrative":"ADAMTS7 is a secreted, cell-surface-retained zinc metalloprotease-proteoglycan of the ADAM-TS family whose extracellular matrix proteolysis drives vascular disease, osteoarthritis, and ectopic tissue remodeling [PMID:10464288, PMID:19168437, PMID:25712206]. The full-length protein (ADAMTS7B) is a chondroitin-sulfate-modified proteoglycan tethered near the cell surface through its ancillary and prodomains, and its catalytic activity requires furin-dependent multistep prodomain removal completed at the cell surface [PMID:15192113]; a prodomain Ser-to-Pro variant (rs3825807) that impairs this maturation reduces substrate cleavage and is associated with protection from disease [PMID:23415669]. ADAMTS7 cleaves an expanding set of matrix and regulatory substrates, including COMP/TSP-5 via its four C-terminal TSP motifs to promote VSMC migration and neointima formation [PMID:16585064, PMID:19168437], thrombospondin-1 to inhibit re-endothelialization and modulate angiogenesis [PMID:25712208, PMID:32005000], LTBP3/LTBP4 and EFEMP1/fibulin-3 [PMID:30926607, PMID:35283288], TIMP-1 to disinhibit MMP-9 and degrade plaque collagen [PMID:37675562], and complement factor H to potentiate complement activation in renal injury [PMID:36735376]. In hyperlipidemic mice, Adamts7 loss reduces atherosclerotic and neointimal lesions, and epistasis experiments establish COMP and TSP-1 degradation as the proteolytic basis of its proatherogenicity [PMID:25712206, PMID:36562301]; in smooth muscle cells it additionally drives foam cell formation through a non-proteolytic AP-1/PU.1/CD36 transcriptional axis that increases oxLDL uptake [PMID:41609669]. In cartilage, ADAMTS7 is a PTHrP transcriptional target that inhibits chondrocyte differentiation and endochondral bone formation, acts as a GEP convertase, and forms a TNF-α/NF-κB positive-feedback loop driving osteoarthritis [PMID:19487464, PMID:20506400, PMID:23928557]. ADAMTS7 functions redundantly with ADAMTS12 to suppress heterotopic ossification and myxomatous valve degeneration [PMID:29618652, PMID:40115634]. TIMP-4 is its most potent endogenous inhibitor, and a structure-based selective small-molecule inhibitor (BAY-9835) has been developed against its catalytic domain [PMID:34587841, PMID:38348661].","teleology":[{"year":1999,"claim":"Established ADAMTS7 as a new member of the ADAM-TS family, defining the multidomain architecture that would later explain its substrate targeting and cell-surface behavior.","evidence":"Primary structure determination and expression profiling during mouse embryogenesis","pmids":["10464288"],"confidence":"High","gaps":["No enzymatic substrate identified","No tissue function assigned"]},{"year":2004,"claim":"Resolved how ADAMTS7 is processed and localized, showing it is a chondroitin-sulfate proteoglycan retained at the cell surface and activated by furin-dependent prodomain removal.","evidence":"Biochemical characterization, GAG analysis, furin inhibition and cleavage assays in HEK293F cells","pmids":["15192113"],"confidence":"High","gaps":["Physiological ECM substrates beyond alpha-2-macroglobulin not yet defined","In vivo relevance of cell-surface retention untested"]},{"year":2006,"claim":"Identified COMP as the first matrix substrate and mapped the binding to ADAMTS7's C-terminal TSP motifs and COMP's EGF repeats, giving the protease a defined cartilage target.","evidence":"Yeast two-hybrid, GST pull-down, co-IP from native cartilage, in vitro digestion with domain mapping","pmids":["16585064"],"confidence":"High","gaps":["In vivo consequence of COMP cleavage unknown at this stage","Did not address vascular roles"]},{"year":2009,"claim":"Connected ADAMTS7 to both cartilage and vascular biology, showing PTHrP-driven inhibition of endochondral ossification via GEP inactivation and injury-induced COMP degradation that promotes VSMC migration.","evidence":"Transgenic and PTHrP-knockout mice, rat carotid balloon injury, overexpression/knockdown, GEP cleavage and substrate rescue assays","pmids":["19487464","19168437"],"confidence":"High","gaps":["Whether COMP is the sole relevant vascular substrate not yet resolved","Endogenous regulation of ADAMTS7 activity incompletely defined"]},{"year":2010,"claim":"Defined GEP as a competitive endogenous regulator that both binds ADAMTS7 and suppresses its TNF-α-induced expression, establishing a layer of substrate-protective control.","evidence":"Yeast two-hybrid, GST pull-down, co-IP, immunofluorescence, in vitro digestion with domain mapping","pmids":["20506400"],"confidence":"High","gaps":["Relative importance of GEP versus other inhibitors in vivo unknown"]},{"year":2013,"claim":"Linked a CAD-associated coding variant to molecular mechanism, showing the rs3825807 prodomain Ser-to-Pro substitution impairs maturation and reduces COMP cleavage and VSMC migration.","evidence":"Genotype-stratified VSMC conditioned media, prodomain cleavage and migration assays","pmids":["23415669"],"confidence":"High","gaps":["Causal in vivo link between variant and atherosclerosis not directly shown","Effect on other substrates untested"]},{"year":2013,"claim":"Established a TNF-α/NF-κB positive-feedback loop driving osteoarthritis, demonstrating cartilage-specific ADAMTS7 overexpression causes spontaneous OA-like disease.","evidence":"Cartilage-specific transgenic and knockdown mice, surgical OA model, NF-κB reporter assay","pmids":["23928557"],"confidence":"High","gaps":["Direct transcriptional targets downstream of ADAMTS7 in feedback loop not defined"]},{"year":2015,"claim":"Provided definitive in vivo genetic validation of ADAMTS7 as proatherogenic and dissected substrate-specific effects: TSP-1 degradation inhibits re-endothelialization while COMP loss is dispensable for that effect.","evidence":"Adamts7-/-, Tsp1-/-, and COMP-/- mice in wire injury and hyperlipidemic models, LC-MS/MS secretome, double-KO epistasis, proliferation assays","pmids":["25712208","25712206","25921940"],"confidence":"High","gaps":["Full substrate repertoire driving lesion formation not yet enumerated","Cell-type origin of pathogenic ADAMTS7 unresolved"]},{"year":2019,"claim":"Expanded the substrate landscape via unbiased N-terminomics, identifying LTBP3/LTBP4 cleavage, defining autolysis sites, and naming TIMP-4 the most potent endogenous inhibitor.","evidence":"TAILS proteomics of fibroblast secretome, N-terminal sequencing, in vitro cleavage with recombinant LTBP4, TIMP inhibitor panel","pmids":["30926607"],"confidence":"High","gaps":["Functional consequence of LTBP cleavage on elastogenesis not directly tested"]},{"year":2022,"claim":"Broadened the vascular substrate set with catalytic-dead-controlled proteomics, identifying 16 substrates including EFEMP1/fibulin-3 with a defined cleavage site.","evidence":"TAILS comparing WT vs E373Q ADAMTS7 in VSMCs and ECs, in vitro binary cleavage of purified EFEMP1","pmids":["35283288"],"confidence":"High","gaps":["In vivo phenotypic relevance of each new substrate not established"]},{"year":2022,"claim":"Demonstrated therapeutic and mechanistic proof by vaccination, showing anti-ADAMTS7 antibodies block COMP and TSP-1 degradation and reduce disease across models, confirming these substrates as the proatherogenic basis.","evidence":"Murine ligation, wire injury, ApoE-/- and LDLR-/- atherosclerosis, swine stent model, in vitro cleavage with vaccine-derived antibodies","pmids":["36562301"],"confidence":"High","gaps":["Durability and off-target effects of vaccination not addressed in timeline"]},{"year":2023,"claim":"Revealed two new pathogenic axes: TIMP-1 degradation that disinhibits MMP-9 and increases plaque collagen turnover, and complement factor H degradation that potentiates complement-driven renal injury.","evidence":"MS of plaques, co-IP, FRET PPI, in vitro degradation with MMP-9 readout; interactome, domain mapping, Adamts7-/- SLE/IR models with AAV-CFH rescue","pmids":["37675562","36735376"],"confidence":"High","gaps":["Relative contribution of TIMP-1 versus matrix substrates to plaque stability not quantified"]},{"year":2024,"claim":"Identified a non-proteolytic transcriptional mechanism in which ADAMTS7 increases chromatin accessibility to drive an AP-1/PU.1/CD36 axis promoting SMC foam cell formation, and showed cell-type-specific transgenic but not knockout effects.","evidence":"SMC- and EC-specific conditional KO/transgenic mice, RNA-seq, ATAC-seq, oxLDL uptake assays, human carotid scRNA-seq","pmids":["41609669"],"confidence":"High","gaps":["How a secreted protease alters intracellular chromatin accessibility mechanistically unresolved","Knockout failing to reduce disease versus prior whole-body KO data not reconciled in timeline"]},{"year":2024,"claim":"Delivered the first structure-based selective inhibitor, using an ADAMTS7 catalytic-domain co-crystal to design BAY-9835 that exploits differences from MMP12.","evidence":"X-ray crystallography, homology modeling, medicinal chemistry, in vitro enzymatic inhibition","pmids":["38348661"],"confidence":"High","gaps":["In vivo efficacy not reported in this study"]},{"year":2024,"claim":"Provided regulatory-genomic context for the CAD locus, linking rs4887091 to a CTCF site and 3D chromatin interactome controlling ADAMTS7 expression in coronary SMCs.","evidence":"snRNA-seq + snATAC-seq from human coronary arteries, caQTL, Hi-C (preprint)","pmids":[],"confidence":"Low","gaps":["No direct functional validation of the variant's effect on ADAMTS7","Preprint, not peer reviewed"]},{"year":2025,"claim":"Established functional redundancy with ADAMTS12 in cardiovascular and connective tissue, showing double-knockout-specific heterotopic ossification and myxomatous valve degeneration with substrate accumulation.","evidence":"Single and double Adamts7/Adamts12 KO mice, electron microscopy, SLRP measurements, echocardiography, TAILS, TGFβ analysis","pmids":["29618652","40115634"],"confidence":"High","gaps":["Molecular basis of compensation between the two proteases not defined","Direct substrate driving valve degeneration not pinpointed"]},{"year":2026,"claim":"Extended ADAMTS7 induction and downstream pathology to new contexts: cigarette-smoke CCL17/CCR4 signaling upregulates vascular ADAMTS7, BAY-9835 protects the post-infarct heart via NF-κB/pyroptosis suppression, and ADAMTS7 promotes cerebral MMP-9 activation worsening stroke outcomes.","evidence":"Cigarette smoke and HFD mouse models, recombinant CCL17, CCR4 siRNA, LAD ligation and MCAO, BAY-9835 pharmacology, transcriptomics (one preprint)","pmids":["42061659","41968389"],"confidence":"Medium","gaps":["CCL17/CCR4 result is a single-lab preprint awaiting peer review","Direct substrate underlying cardioprotective and cerebral MMP-9 effects not identified"]},{"year":null,"claim":"How a secreted, cell-surface protease executes the non-proteolytic intracellular chromatin/AP-1/PU.1/CD36 program, and which specific substrate cleavages dominate each disease context, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["Mechanism coupling extracellular ADAMTS7 to nuclear chromatin remodeling unknown","Discordance between conditional-KO and whole-body-KO atherosclerosis phenotypes unexplained","Hierarchy of substrate importance across vascular, renal, cardiac, and cerebral pathology undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,5,9,11,13,15,16]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,2,19]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[18]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,9,11]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,10]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[4,17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[2,4,9,11,13,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,14,16,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[16,24]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,8,17,23]}],"complexes":[],"partners":["COMP","THBS1","GRN","TIMP4","LTBP4","EFEMP1","TIMP1","CFH"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UKP4","full_name":"A disintegrin and metalloproteinase with thrombospondin motifs 7","aliases":[],"length_aa":1686,"mass_kda":184.1,"function":"Metalloprotease (PubMed:16585064, PubMed:39672391). Was previously shown to degrade COMP (PubMed:16585064). However, a later study found no activity against COMP (PubMed:39672391)","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q9UKP4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADAMTS7","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":383,"dependency_fraction":0.0026109660574412533},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADAMTS7","total_profiled":1310},"omim":[{"mim_id":"613382","title":"BRACHYDACTYLY, TYPE E2; BDE2","url":"https://www.omim.org/entry/613382"},{"mim_id":"611681","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 20; ADAMTS20","url":"https://www.omim.org/entry/611681"},{"mim_id":"606184","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 12; ADAMTS12","url":"https://www.omim.org/entry/606184"},{"mim_id":"605009","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 7; ADAMTS7","url":"https://www.omim.org/entry/605009"},{"mim_id":"605008","title":"A DISINTEGRIN-LIKE AND METALLOPROTEINASE WITH THROMBOSPONDIN TYPE 1 MOTIF, 6; ADAMTS6","url":"https://www.omim.org/entry/605008"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":14.2},{"tissue":"heart muscle","ntpm":28.7}],"url":"https://www.proteinatlas.org/search/ADAMTS7"},"hgnc":{"alias_symbol":["ADAM-TS7","DKFZp434H204"],"prev_symbol":[]},"alphafold":{"accession":"Q9UKP4","domains":[{"cath_id":"3.40.1620.60","chopping":"41-65_76-102_127-185_462-535","consensus_level":"medium","plddt":67.6556,"start":41,"end":535},{"cath_id":"3.40.390.10","chopping":"242-388_434-449","consensus_level":"medium","plddt":84.076,"start":242,"end":449},{"cath_id":"-","chopping":"558-671","consensus_level":"medium","plddt":83.0103,"start":558,"end":671},{"cath_id":"2.60.120.830","chopping":"698-810","consensus_level":"high","plddt":89.412,"start":698,"end":810},{"cath_id":"2.20.100","chopping":"824-875","consensus_level":"high","plddt":80.385,"start":824,"end":875},{"cath_id":"-","chopping":"881-919","consensus_level":"medium","plddt":79.2228,"start":881,"end":919}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UKP4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UKP4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UKP4-F1-predicted_aligned_error_v6.png","plddt_mean":63.72},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADAMTS7","jax_strain_url":"https://www.jax.org/strain/search?query=ADAMTS7"},"sequence":{"accession":"Q9UKP4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UKP4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UKP4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UKP4"}},"corpus_meta":[{"pmid":"21239051","id":"PMC_21239051","title":"Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies.","date":"2011","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21239051","citation_count":423,"is_preprint":false},{"pmid":"19168437","id":"PMC_19168437","title":"ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries.","date":"2009","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/19168437","citation_count":185,"is_preprint":false},{"pmid":"10464288","id":"PMC_10464288","title":"ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10464288","citation_count":172,"is_preprint":false},{"pmid":"16585064","id":"PMC_16585064","title":"ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/16585064","citation_count":135,"is_preprint":false},{"pmid":"25712208","id":"PMC_25712208","title":"ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1.","date":"2015","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/25712208","citation_count":128,"is_preprint":false},{"pmid":"20506400","id":"PMC_20506400","title":"Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein.","date":"2010","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/20506400","citation_count":115,"is_preprint":false},{"pmid":"18485748","id":"PMC_18485748","title":"Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin.","date":"2008","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/18485748","citation_count":114,"is_preprint":false},{"pmid":"25712206","id":"PMC_25712206","title":"Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice.","date":"2015","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/25712206","citation_count":109,"is_preprint":false},{"pmid":"19487464","id":"PMC_19487464","title":"ADAMTS-7, a direct target of PTHrP, adversely regulates endochondral bone growth by associating with and inactivating GEP growth factor.","date":"2009","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19487464","citation_count":95,"is_preprint":false},{"pmid":"23415669","id":"PMC_23415669","title":"ADAMTS7 cleavage and vascular smooth muscle cell migration is affected by a coronary-artery-disease-associated variant.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23415669","citation_count":89,"is_preprint":false},{"pmid":"15192113","id":"PMC_15192113","title":"ADAMTS7B, the full-length product of the ADAMTS7 gene, is a chondroitin sulfate proteoglycan containing a mucin domain.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15192113","citation_count":80,"is_preprint":false},{"pmid":"19098927","id":"PMC_19098927","title":"The role of ADAMTS-7 and ADAMTS-12 in the pathogenesis of arthritis.","date":"2009","source":"Nature clinical practice. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/19098927","citation_count":73,"is_preprint":false},{"pmid":"23928557","id":"PMC_23928557","title":"ADAMTS-7 forms a positive feedback loop with TNF-α in the pathogenesis of osteoarthritis.","date":"2013","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23928557","citation_count":69,"is_preprint":false},{"pmid":"36562301","id":"PMC_36562301","title":"Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/36562301","citation_count":61,"is_preprint":false},{"pmid":"30926607","id":"PMC_30926607","title":"Proteomic discovery of substrates of the cardiovascular protease ADAMTS7.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30926607","citation_count":49,"is_preprint":false},{"pmid":"28461624","id":"PMC_28461624","title":"Loss of Cardioprotective Effects at the ADAMTS7 Locus as a Result of Gene-Smoking Interactions.","date":"2017","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/28461624","citation_count":46,"is_preprint":false},{"pmid":"37675562","id":"PMC_37675562","title":"ADAMTS-7 Modulates Atherosclerotic Plaque Formation by Degradation of TIMP-1.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/37675562","citation_count":45,"is_preprint":false},{"pmid":"29618652","id":"PMC_29618652","title":"The metalloproteinase-proteoglycans ADAMTS7 and ADAMTS12 provide an innate, tendon-specific protective mechanism against heterotopic ossification.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29618652","citation_count":42,"is_preprint":false},{"pmid":"22247065","id":"PMC_22247065","title":"Negative effects of ADAMTS-7 and ADAMTS-12 on endplate cartilage differentiation.","date":"2012","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/22247065","citation_count":36,"is_preprint":false},{"pmid":"28623250","id":"PMC_28623250","title":"ADAMTS-7 is associated with a high-risk plaque phenotype in human atherosclerosis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28623250","citation_count":35,"is_preprint":false},{"pmid":"26696755","id":"PMC_26696755","title":"The Function and Roles of ADAMTS-7 in Inflammatory Diseases.","date":"2015","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/26696755","citation_count":28,"is_preprint":false},{"pmid":"26446668","id":"PMC_26446668","title":"IL-17A enhances ADAMTS-7 expression through regulation of TNF-α in human nucleus pulposus cells.","date":"2015","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/26446668","citation_count":26,"is_preprint":false},{"pmid":"30903650","id":"PMC_30903650","title":"Wnt and RUNX2 mediate cartilage breakdown by osteoarthritis synovial fibroblast-derived ADAMTS-7 and -12.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30903650","citation_count":25,"is_preprint":false},{"pmid":"20717629","id":"PMC_20717629","title":"ADAMTS-7, a novel proteolytic culprit in vascular remodeling.","date":"2010","source":"Sheng li xue bao : [Acta physiologica Sinica]","url":"https://pubmed.ncbi.nlm.nih.gov/20717629","citation_count":23,"is_preprint":false},{"pmid":"24222922","id":"PMC_24222922","title":"Biochemistry and physiological functions of ADAMTS7 metalloprotease.","date":"2013","source":"Advances in biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24222922","citation_count":22,"is_preprint":false},{"pmid":"21869572","id":"PMC_21869572","title":"Expression of ADAMTS-7 and ADAMTS-12 in the nucleus pulposus during degeneration of rat caudal intervetebral disc.","date":"2011","source":"The Journal of veterinary medical science","url":"https://pubmed.ncbi.nlm.nih.gov/21869572","citation_count":22,"is_preprint":false},{"pmid":"25921940","id":"PMC_25921940","title":"ADAMTS-7 promotes vascular smooth muscle cells proliferation in vitro and in vivo.","date":"2015","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25921940","citation_count":21,"is_preprint":false},{"pmid":"29089340","id":"PMC_29089340","title":"Genetic Variation at the ADAMTS7 Locus is Associated With Reduced Severity of Coronary Artery Disease.","date":"2017","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/29089340","citation_count":20,"is_preprint":false},{"pmid":"23829786","id":"PMC_23829786","title":"ADAMTS7: a promising new therapeutic target in coronary heart disease.","date":"2013","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/23829786","citation_count":18,"is_preprint":false},{"pmid":"25653475","id":"PMC_25653475","title":"ADAMTS-7 exhibits elevated expression in cartilage of osteonecrosis of femoral head and has a positive correlation with TNF- α and NF- κ B P65.","date":"2015","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25653475","citation_count":18,"is_preprint":false},{"pmid":"25885961","id":"PMC_25885961","title":"Association between plasma ADAMTS-7 levels and ventricular remodeling in patients with acute myocardial infarction.","date":"2015","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/25885961","citation_count":18,"is_preprint":false},{"pmid":"35283288","id":"PMC_35283288","title":"TAILS Identifies Candidate Substrates and Biomarkers of ADAMTS7, a Therapeutic Protease Target in Coronary Artery Disease.","date":"2022","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/35283288","citation_count":16,"is_preprint":false},{"pmid":"27614204","id":"PMC_27614204","title":"Association of ADAMTS7 gene polymorphism with cardiovascular survival in coronary artery disease.","date":"2016","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27614204","citation_count":16,"is_preprint":false},{"pmid":"24642842","id":"PMC_24642842","title":"ADAMTS-7 expression increases in the early stage of angiotensin II-induced renal injury in elderly mice.","date":"2014","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/24642842","citation_count":16,"is_preprint":false},{"pmid":"31894258","id":"PMC_31894258","title":"Upregulation of miR‑423 improves autologous vein graft restenosis via targeting ADAMTS‑7.","date":"2019","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31894258","citation_count":13,"is_preprint":false},{"pmid":"28205274","id":"PMC_28205274","title":"Genetic variants rs1994016 and rs3825807 in ADAMTS7 affect its mRNA expression in atherosclerotic occlusive peripheral arterial disease.","date":"2017","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/28205274","citation_count":12,"is_preprint":false},{"pmid":"28849199","id":"PMC_28849199","title":"Upregulation of ADAMTS‑7 and downregulation of COMP are associated with aortic aneurysm.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28849199","citation_count":12,"is_preprint":false},{"pmid":"37354304","id":"PMC_37354304","title":"ADAMTS7: a Novel Therapeutic Target in Atherosclerosis.","date":"2023","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/37354304","citation_count":11,"is_preprint":false},{"pmid":"26189211","id":"PMC_26189211","title":"ADAMTS7 locus confers high cross-race risk for development of coronary atheromatous plaque.","date":"2015","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/26189211","citation_count":11,"is_preprint":false},{"pmid":"26938210","id":"PMC_26938210","title":"Association of ADAMTS-7 Levels with Cardiac Function in a Rat Model of Acute Myocardial Infarction.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26938210","citation_count":11,"is_preprint":false},{"pmid":"26872430","id":"PMC_26872430","title":"Classification of ADAMTS binding sites: The first step toward selective ADAMTS7 inhibitors.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26872430","citation_count":10,"is_preprint":false},{"pmid":"34587841","id":"PMC_34587841","title":"Development of a fluorogenic ADAMTS-7 substrate.","date":"2021","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34587841","citation_count":10,"is_preprint":false},{"pmid":"36662289","id":"PMC_36662289","title":"ADAMTS-7 deficiency attenuates thoracic aortic aneurysm and dissection in mice.","date":"2023","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36662289","citation_count":10,"is_preprint":false},{"pmid":"38348661","id":"PMC_38348661","title":"BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38348661","citation_count":9,"is_preprint":false},{"pmid":"35462367","id":"PMC_35462367","title":"miR-654-5p Suppresses Migration and Proliferation of Vascular Smooth Muscle Cells by Targeting ADAMTS-7.","date":"2022","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/35462367","citation_count":9,"is_preprint":false},{"pmid":"33122452","id":"PMC_33122452","title":"Association of polymorphisms in ADAMTS-7 gene with the susceptibility to coronary artery disease - a systematic review and meta-analysis.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33122452","citation_count":9,"is_preprint":false},{"pmid":"32005000","id":"PMC_32005000","title":"Effect of a coronary-heart-disease-associated variant of ADAMTS7 on endothelial cell angiogenesis.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32005000","citation_count":8,"is_preprint":false},{"pmid":"32250736","id":"PMC_32250736","title":"Hypomethylation of DNA promoter upregulates ADAMTS7 and contributes to HTR-8/SVneo and JEG-3 cells abnormalities in pre-eclampsia.","date":"2020","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/32250736","citation_count":8,"is_preprint":false},{"pmid":"36735376","id":"PMC_36735376","title":"ADAMTS7-Mediated Complement Factor H Degradation Potentiates Complement Activation to Contributing to Renal Injuries.","date":"2023","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/36735376","citation_count":7,"is_preprint":false},{"pmid":"32692461","id":"PMC_32692461","title":"ADAMTS7 degrades Comp to fuel BMP2-dependent osteogenic differentiation and ameliorate oncogenic potential in osteosarcomas.","date":"2020","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/32692461","citation_count":7,"is_preprint":false},{"pmid":"31460868","id":"PMC_31460868","title":"Genetic variants of ADAMTS7 confer risk for ischaemic stroke in the Chinese population.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31460868","citation_count":6,"is_preprint":false},{"pmid":"29980058","id":"PMC_29980058","title":"Association of serum ADAMTS7 levels and genetic variant rs1994016 with acute coronary syndrome in a Chinese population: A case control study.","date":"2018","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/29980058","citation_count":6,"is_preprint":false},{"pmid":"36677041","id":"PMC_36677041","title":"New Markers for Cardiovascular Disease in Psoriatic Patients: Preliminary Study on Monocyte Phenotype, ADAMTS7, and mTOR Activity.","date":"2023","source":"Metabolites","url":"https://pubmed.ncbi.nlm.nih.gov/36677041","citation_count":5,"is_preprint":false},{"pmid":"30720083","id":"PMC_30720083","title":"Upregulation of ADAMTS‑7 and downregulation of COMP are associated with spontaneous abortion.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30720083","citation_count":5,"is_preprint":false},{"pmid":"38463994","id":"PMC_38463994","title":"ADAMTS7 Promotes Smooth Muscle Foam Cell Expansion in Atherosclerosis.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38463994","citation_count":4,"is_preprint":false},{"pmid":"40115634","id":"PMC_40115634","title":"ADAMTS7, a target in atherosclerosis, cooperates with its homolog ADAMTS12 to protect against myxomatous valve degeneration.","date":"2025","source":"Journal of molecular and cellular cardiology plus","url":"https://pubmed.ncbi.nlm.nih.gov/40115634","citation_count":4,"is_preprint":false},{"pmid":"36831113","id":"PMC_36831113","title":"Non-Canonical WNT/Wnt5a Pathway Activity in Circulating Monocytes of Untreated Psoriatic Patients: An Exploratory Study of Its Association with Inflammatory Cytokines and Cardiovascular Risk Marker-ADAMTS7.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36831113","citation_count":4,"is_preprint":false},{"pmid":"39149096","id":"PMC_39149096","title":"Design, synthesis and biological evaluation of arylsulfonamides as ADAMTS7 inhibitors.","date":"2024","source":"RSC medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39149096","citation_count":3,"is_preprint":false},{"pmid":"38528617","id":"PMC_38528617","title":"Diagnostic value of serum COMP and ADAMTS7 for intervertebral disc degeneration.","date":"2024","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/38528617","citation_count":3,"is_preprint":false},{"pmid":"38396951","id":"PMC_38396951","title":"The Association of ADAMTS7 Gene Polymorphisms with the Risk of Coronary Artery Disease Occurrence and Cardiovascular Survival in the Polish Population: A Case-Control and a Prospective Cohort Study.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38396951","citation_count":3,"is_preprint":false},{"pmid":"36833435","id":"PMC_36833435","title":"The rs3825807 Polymorphism of ADAMTS7 as a Potential Genetic Marker for Myocardial Infarction in Slovenian Subjects with Type 2 Diabetes Mellitus.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36833435","citation_count":3,"is_preprint":false},{"pmid":"39768861","id":"PMC_39768861","title":"Association Between Plasma ADAMTS-7 Levels and Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus.","date":"2024","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/39768861","citation_count":3,"is_preprint":false},{"pmid":"29624002","id":"PMC_29624002","title":"Expression of ADAMTS-7 in myocardial dystrophy associated with white muscle disease in lambs.","date":"2018","source":"Polish journal of veterinary sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29624002","citation_count":3,"is_preprint":false},{"pmid":"34169731","id":"PMC_34169731","title":"Investigating ADAMTS7 and ADAMTS12 levels in prediabetic and Type 2 diabetic patients.","date":"2021","source":"Biomarkers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34169731","citation_count":2,"is_preprint":false},{"pmid":"39781347","id":"PMC_39781347","title":"ADAMTS7 Enhances Gastric Cancer Growth and Metastasis by Triggering the NF-κB Signaling Pathway.","date":"2025","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39781347","citation_count":2,"is_preprint":false},{"pmid":"41609669","id":"PMC_41609669","title":"ADAMTS7 promotes smooth muscle foam cell expansion in atherosclerosis.","date":"2026","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/41609669","citation_count":1,"is_preprint":false},{"pmid":"35503474","id":"PMC_35503474","title":"ADAMTS7 Attenuates House Dust Mite-Induced Airway Inflammation and Th2 Immune Responses.","date":"2022","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/35503474","citation_count":1,"is_preprint":false},{"pmid":"32441044","id":"PMC_32441044","title":"Elevated serum cartilage oligomeric matrix protein and the metalloproteinase-ADAMTS7 levels are associated with vascular calcification in maintenance hemodialysis patients.","date":"2020","source":"Seminars in dialysis","url":"https://pubmed.ncbi.nlm.nih.gov/32441044","citation_count":1,"is_preprint":false},{"pmid":"41920022","id":"PMC_41920022","title":"The biology and pathophysiology of the proatherogenic metalloprotease ADAMTS7.","date":"2026","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/41920022","citation_count":0,"is_preprint":false},{"pmid":"40565590","id":"PMC_40565590","title":"Direct Oral Anticoagulant-Related Bleeding in Atrial Fibrillation Patients Leads to ADAMTS7 Promoter Demethylation.","date":"2025","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/40565590","citation_count":0,"is_preprint":false},{"pmid":"38536049","id":"PMC_38536049","title":"Circ_0104652 Promotes the Proliferation and Migration of ox-LDL-Stimulated Vascular Smooth Muscle Cells via Stabilizing ADAMTS7 and HMGB1.","date":"2024","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/38536049","citation_count":0,"is_preprint":false},{"pmid":"42184821","id":"PMC_42184821","title":"A functional polymorphism in ADAMTS7 3'-UTR abrogates miR-654-5p-mediated ADAMTS7 expression suppression and increases the incidence, short-term outcome, and recurrence of large artery atherosclerotic stroke among southern Chinese population.","date":"2026","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/42184821","citation_count":0,"is_preprint":false},{"pmid":"41898876","id":"PMC_41898876","title":"Genetic Variants and Molecular Components Associated with Metabolic Dysfunctional-Associated Steatotic Liver Disease and Depression: Shared Association of ADAMTS7 and THRAP3.","date":"2026","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/41898876","citation_count":0,"is_preprint":false},{"pmid":"42061659","id":"PMC_42061659","title":"ADAMTS7 selective inhibitor BAY-9835 alleviates acute myocardial infarction by suppressing the NF-κB-mediated pyroptosis.","date":"2026","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/42061659","citation_count":0,"is_preprint":false},{"pmid":"41968389","id":"PMC_41968389","title":"ADAMTS-7 Increase Contributes to Worsened Neurological Outcome in Mice on High Fat Diet.","date":"2026","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/41968389","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.28.685237","title":"Cigarette smoking upregulates vascular expression of the novel atherosclerosis risk factor ADAMTS-7","date":"2025-10-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.28.685237","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.13.24317257","title":"Single cell variant to enhancer to gene map for coronary artery disease","date":"2024-11-13","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.13.24317257","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43223,"output_tokens":7834,"usd":0.12359,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17542,"output_tokens":5644,"usd":0.114405,"stage2_stop_reason":"end_turn"},"total_usd":0.237995,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"ADAMTS7 (ADAM-TS7) was identified as a novel zinc metalloprotease with a domain organization comprising a preproregion, a reprolysin-type catalytic domain, a disintegrin-like domain, a thrombospondin type-1 (TS) module, a cysteine-rich domain, a spacer domain, and a C-terminal TS module, placing it in the ADAM-TS family of reprolysin-like metalloproteases.\",\n      \"method\": \"Primary structure determination, genomic distribution analysis, expression profiling during mouse embryogenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — foundational structural characterization with cloning and domain architecture, replicated across family members in same study\",\n      \"pmids\": [\"10464288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ADAMTS7B, the full-length product of the ADAMTS7 gene, is a proteoglycan modified by chondroitin sulfate attachment within a unique mucin domain, is retained near the cell surface via interactions involving the ancillary domain and prodomain, undergoes furin-dependent multistep prodomain removal (with final cleavage at the cell surface after Arg220), and is an active metalloproteinase capable of cleaving alpha-2-macroglobulin but does not cleave versican or aggrecan.\",\n      \"method\": \"Protein characterization, glycosaminoglycan analysis, furin inhibition assay, in vitro cleavage assay, subcellular localization studies in HEK293F cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (biochemical characterization, mutagenesis-equivalent inhibitor studies, cleavage assays) in a single rigorous study establishing structure-function\",\n      \"pmids\": [\"15192113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ADAMTS-7 directly binds to and degrades cartilage oligomeric matrix protein (COMP); binding is mediated by the EGF repeat domain of COMP and the four C-terminal TSP motifs of ADAMTS-7; the recombinant catalytic domain and intact ADAMTS-7 cleave COMP in vitro in a Zn2+- and pH-dependent manner (optimal pH 7.5–9.5).\",\n      \"method\": \"Yeast two-hybrid screen, in vitro GST pull-down, co-immunoprecipitation from native articular cartilage, in vitro digestion assay, domain-mapping experiments\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with domain mapping, yeast two-hybrid plus co-IP in native tissue, multiple orthogonal methods\",\n      \"pmids\": [\"16585064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ADAMTS-7 cleaves alpha-2-macroglobulin (α2M) in vitro, generating 180- and 105-kDa cleavage products; α2M in turn inhibits ADAMTS-7-mediated COMP degradation in a concentration-dependent manner, representing the first identified endogenous inhibitor of ADAMTS-7.\",\n      \"method\": \"In vitro digestion assay, siRNA knockdown in human chondrocytes, blocking antibodies in cartilage explants\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro cleavage assay with functional inhibition demonstrated, corroborated by siRNA and antibody approaches\",\n      \"pmids\": [\"18485748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADAMTS-7 mediates vascular smooth muscle cell (VSMC) migration and neointima formation; ADAMTS-7 protein accumulates in neointima after balloon injury; TNF-α and PDGF-BB induce ADAMTS-7 expression; ADAMTS-7 facilitates VSMC migration through degradation of COMP, its vascular ECM substrate; COMP replenishment circumvents the pro-migratory effect.\",\n      \"method\": \"Rat carotid artery balloon injury model, adenovirus overexpression, siRNA knockdown in vivo and in vitro, VSMC migration/invasion assays, immunohistochemistry\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain- and loss-of-function in vivo with substrate rescue experiment, multiple orthogonal methods, replicated in vitro and in vivo\",\n      \"pmids\": [\"19168437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ADAMTS-7 is a direct transcriptional target of PTHrP signaling in chondrocytes; it inhibits chondrocyte differentiation and endochondral bone formation in a proteolytic activity-dependent manner; the cysteine-rich domain is required for ECM interaction; the C-terminal four TSP motifs are required for full proteolytic activity; ADAMTS-7 associates with and proteolytically inactivates GEP (granulin-epithelin precursor), acting as a GEP convertase to neutralize GEP-stimulated endochondral bone formation.\",\n      \"method\": \"Transgenic mice, PTHrP knockout mice, ADAMTS-7 overexpression/knockdown, reporter gene assay, domain-deletion constructs, in vitro GEP cleavage assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vivo genetic models with mechanistic rescue, in vitro enzymatic cleavage, domain-mapping, epistasis with PTHrP pathway\",\n      \"pmids\": [\"19487464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Granulin-epithelin precursor (GEP) directly binds ADAMTS-7 via its C-terminal four TSP motifs (ADAMTS-7 side) and each granulin unit (GEP side); GEP co-localizes with ADAMTS-7 on the chondrocyte cell surface; GEP inhibits ADAMTS-7-mediated COMP degradation through competitive inhibition via direct protein-protein interactions and by suppressing TNF-α-induced ADAMTS-7 expression.\",\n      \"method\": \"Yeast two-hybrid, GST pull-down, co-immunoprecipitation, immunofluorescence co-localization, in vitro digestion assay, domain-mapping\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal binding methods plus functional enzymatic inhibition, domain-level mapping\",\n      \"pmids\": [\"20506400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A non-synonymous SNP rs3825807 (Ser-to-Pro substitution) in the ADAMTS7 prodomain reduces prodomain cleavage/maturation of the protease in VSMCs, resulting in less cleaved thrombospondin-5 (COMP/TSP-5) in conditioned media and reduced VSMC migratory ability; the protective G allele is associated with reduced ADAMTS7 function.\",\n      \"method\": \"Genotyped VSMC conditioned media analysis, prodomain cleavage assays, VSMC migration assays in cells stratified by genotype\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical cleavage assay linking SNP to altered prodomain processing and substrate cleavage, functional migration readout, multiple methods in one study\",\n      \"pmids\": [\"23415669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAMTS-7 and TNF-α form a positive feedback loop in osteoarthritis: TNF-α induces ADAMTS-7 expression via NF-κB signaling, while ADAMTS-7 overexpression upregulates TNF-α and metalloproteinases; cartilage-specific ADAMTS-7 overexpression leads to chondrodysplasia and spontaneous OA-like phenotype; knockdown attenuates OA progression.\",\n      \"method\": \"Cartilage-specific ADAMTS-7 transgenic mice, siRNA knockdown mice, surgically-induced OA model, NF-κB reporter gene assay, immunohistochemistry\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gain- and loss-of-function genetic models, reporter assay establishing NF-κB pathway, replicated across multiple OA models\",\n      \"pmids\": [\"23928557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADAMTS-7 inhibits re-endothelialization of injured arteries by degrading thrombospondin-1 (TSP-1); ADAMTS-7 directly associates with TSP-1 via its C-terminus and degrades TSP-1 in vivo and in vitro; Adamts7-/- mice show greatly promoted re-endothelialization and reduced neointima formation; the inhibitory effect of ADAMTS-7 on endothelium recovery is abolished in Tsp1-/- mice (but not in COMP-/- mice), demonstrating TSP-1 as the relevant substrate for this effect.\",\n      \"method\": \"Adamts7-/- and Tsp1-/- mouse wire injury models, Evans blue staining, label-free LC-MS/MS secretome analysis, in vitro co-association and degradation assays, endothelial cell proliferation/migration assays\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo (double KO rescue), in vitro biochemical confirmation, mass spectrometry substrate discovery, multiple orthogonal methods\",\n      \"pmids\": [\"25712208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Adamts7 knockout in hyperlipidemic mouse models (Ldlr-/- and Apoe-/-) significantly reduces atherosclerotic lesion formation and neointimal formation; ADAMTS7 is proatherogenic; ADAMTS7 co-localizes with smooth muscle cell markers in human CAD lesions and localizes to the cytoplasm and cell membrane in cultured VSMCs, co-localizing with podosome markers; primary Adamts7-/- VSMCs show reduced migration under TNF-α stimulation.\",\n      \"method\": \"Whole-body knockout mice crossed to hyperlipidemic backgrounds, femoral wire injury model, VSMC migration assays, subcellular localization studies, immunohistochemistry of human lesions\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — first in vivo genetic validation in two atherosclerosis models, human tissue corroboration, subcellular localization with functional correlate\",\n      \"pmids\": [\"25712206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TAILS unbiased substrate profiling identified LTBP3 and LTBP4 as ADAMTS7 substrates; ADAMTS7 cleaves LTBP4 at multiple sites in an N-terminal linker region connecting fibulin-5/tropoelastin and fibrillin-1-binding regions; ADAMTS7 undergoes autolysis at Glu729-Val730 and Glu732-Ala733 in the Spacer domain; TIMP-4 is the most potent endogenous inhibitor of ADAMTS7 (compared to TIMP-1, -2, -3).\",\n      \"method\": \"TAILS proteomic substrate analysis of human fibroblast secretome, N-terminal sequencing, Western blotting, in vitro cleavage assay with purified ADAMTS7 and recombinant LTBP4, metalloprotease inhibitor panel\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — unbiased proteomics plus in vitro reconstitution with purified components and N-terminal sequencing confirmation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30926607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Wnt/β-catenin signaling (induced by IL-1β or Wnt7B) drives ADAMTS-7 expression in osteoarthritis synovial fibroblasts, and ADAMTS-7 from synovial fibroblasts contributes to COMP degradation in cartilage; blockade of Wnt signaling by DKK1 reduces ADAMTS-7 expression and COMP degradation.\",\n      \"method\": \"OA synovial fibroblast cultures, ERK inhibition, DKK1 Wnt pathway blockade, COMP degradation assays\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, pharmacological pathway inhibition with functional readout but no direct epistasis\",\n      \"pmids\": [\"30903650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TAILS in vascular smooth muscle and endothelial cells identified 24 unique cleavage sites from 16 protein substrates of ADAMTS7; EFEMP1 (Fibulin-3) was identified as an ADAMTS7 substrate with a preferred cleavage site at amino acids 123–124, validated by in vitro binary cleavage assay with purified EFEMP1.\",\n      \"method\": \"TAILS with ADAMTS7 WT vs. catalytic mutant (E373Q) adenovirus expression in VSMCs and ECs, in vitro binary cleavage assay with purified EFEMP1\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — unbiased proteomics with catalytic dead mutant negative control plus in vitro reconstitution with purified substrate, multiple independent TAILS experiments\",\n      \"pmids\": [\"35283288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Vaccination with a peptide (ATS7vac) derived from ADAMTS7 generates specific antibodies that inhibit ADAMTS-7-mediated COMP and TSP-1 degradation, suppress VSMC migration, and promote re-endothelialization, confirming COMP and TSP-1 degradation as the mechanistic basis of ADAMTS7 proatherogenicity.\",\n      \"method\": \"Murine carotid artery ligation, wire injury, atherosclerosis models (ApoE-/- and LDLR-/-), swine coronary stent model, in vitro substrate cleavage assays with vaccination-derived antibodies\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple animal models with mechanistic readout, in vitro substrate cleavage confirmation, translational validation in pigs\",\n      \"pmids\": [\"36562301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAMTS-7 binds to and degrades TIMP-1 via its catalytic domain; ADAMTS-7-mediated TIMP-1 degradation reduces TIMP-1's inhibitory capacity on MMP-9, leading to increased MMP-9 activity and collagen degradation in atherosclerotic plaques; Adamts7-/- atherosclerotic aortas show higher TIMP-1 levels and greater collagen content.\",\n      \"method\": \"Mass spectrometry of atherosclerotic plaques from Apoe-/- vs. Apoe-/-Adamts7-/- mice, co-immunoprecipitation, FRET-based protein-protein interaction assay, in vitro degradation assay, Picrosirius red collagen staining\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — unbiased mass spectrometry identification followed by co-IP, FRET PPI assay, and in vitro degradation reconstitution with functional downstream MMP-9 readout, multiple orthogonal methods\",\n      \"pmids\": [\"37675562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAMTS7 binds to complement factor H (CFH) at CCP domains 1–4 and degrades the CCP 1–7 domain through multiple cleavages; ADAMTS7 deficiency alleviates complement activation and related renal pathologies in lupus nephritis and renal ischemia-reperfusion injury models; adeno-associated virus-mediated CFH silencing abolished the protective effects of ADAMTS7 knockout, establishing the ADAMTS7→CFH degradation→complement activation axis.\",\n      \"method\": \"Unbiased interactome of lupus mice kidneys, in vitro cleavage assay, Adamts7-/- mouse models of SLE and renal I/R injury, AAV-mediated CFH silencing rescue experiment\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro cleavage reconstitution, domain mapping, genetic epistasis rescue in vivo with AAV-CFH silencing, multiple orthogonal approaches\",\n      \"pmids\": [\"36735376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ADAMTS7 and ADAMTS12 together protect against heterotopic ossification (HO) in hindlimb tendons, menisci, and ligaments; Adamts7-/-Adamts12-/- double-knockout mice (but not single knockouts) develop progressive HO, accompanied by abnormal collagen fibrils and reduced levels of the SLRPs biglycan, fibromodulin, and decorin, implicating these proteoglycans as downstream mediators.\",\n      \"method\": \"Single and double knockout mouse models, histology, collagen fibril analysis by electron microscopy, SLRP protein level measurements\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via single vs. double knockout establishing functional redundancy, with mechanistic substrate/downstream effector identification\",\n      \"pmids\": [\"29618652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADAMTS7 promotes smooth muscle cell (SMC) foam cell formation and atherosclerosis via an AP-1/PU.1/CD36 regulatory axis: ADAMTS7 expression increases chromatin accessibility at AP-1-enriched regions, upregulating PU.1 (a myeloid transcription factor), which in turn increases CD36 expression and oxidized LDL uptake by SMCs; SMC-specific and EC-specific Adamts7 conditional transgenic mice both show increased atherosclerosis, whereas conditional knockout in either cell type does not reduce atherosclerosis.\",\n      \"method\": \"SMC- and EC-specific conditional KO and transgenic mice, RNA-seq, ATAC-seq with motif analysis, oxLDL uptake assays, single-cell RNA-seq of human carotid atherosclerosis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic models, multi-omics (RNA-seq, ATAC-seq), functional assay, human tissue validation, multiple orthogonal methods\",\n      \"pmids\": [\"41609669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BAY-9835, the first orally bioavailable selective ADAMTS7 inhibitor, was designed using X-ray co-crystal structure of the ADAMTS7 catalytic domain to exploit amino acid differences between ADAMTS7 and MMP12 binding sites; the compound selectively inhibits the ADAMTS7 catalytic zinc-containing metalloproteinase domain.\",\n      \"method\": \"X-ray crystallography co-crystal structure, in silico homology modeling, medicinal chemistry optimization, in vitro enzymatic inhibition assays\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure-based design with in vitro enzymatic validation, first structural data on ADAMTS7 catalytic domain-inhibitor interaction\",\n      \"pmids\": [\"38348661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A fluorogenic FRET substrate (ATS7FP7) was developed for ADAMTS7 activity measurement; TIMP-4 shows the highest inhibitory potency among TIMPs for ADAMTS7 (confirmed with both fluorogenic substrate and SDS-PAGE assay using LTBP4S-A), supporting TIMP-4 as the primary physiological inhibitor.\",\n      \"method\": \"Fluorogenic FRET substrate assay development, inhibition constant measurements for TIMP-1/-2/-3/-4 and hydroxamate inhibitors\",\n      \"journal\": \"Journal of enzyme inhibition and medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro enzymatic assay with purified components, single lab, but confirms prior TIMP-4 finding with new orthogonal method\",\n      \"pmids\": [\"34587841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ADAMTS-7 promotes VSMC proliferation in vitro and in vivo; adenoviral ADAMTS-7 overexpression increases the percentage of PCNA-positive cells in intima and media after injury; siRNA knockdown reduces intimal VSMC replication; [3H]-thymidine incorporation assay shows 61% enhanced and 23% reduced replication with overexpression and knockdown respectively.\",\n      \"method\": \"Rat carotid artery injury model with adenoviral delivery, perivascular siRNA administration, [3H]-thymidine incorporation assay in primary VSMCs, PCNA immunostaining\",\n      \"journal\": \"Science China. Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in vivo and in vitro with quantitative proliferation readouts, single lab\",\n      \"pmids\": [\"25921940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADAMTS7 promotes angiogenesis in endothelial cells via TSP-1 degradation: ADAMTS7 knockdown attenuates EC migration and tube formation; ADAMTS7-Ser214 overexpression increases these; proteomics shows inverse TSP-1 levels in conditioned media correlating with ADAMTS7 status; the pro-angiogenic effect is abolished by a TSP-1 blocking antibody; the Ser214Pro substitution (CAD-protective variant) reduces TSP-1 degrading activity.\",\n      \"method\": \"ADAMTS7 knockdown/overexpression in ECs, proteomics of conditioned media, TSP-1 cleavage assay, tube formation and migration assays, TSP-1 blocking antibody rescue\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (proteomics, functional rescue, cleavage assay), single lab\",\n      \"pmids\": [\"32005000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ADAMTS7 and ADAMTS12 are co-expressed in heart valves and each compensates for loss of the other by upregulation; Adamts7-/-Adamts12-/- double knockout mice develop myxomatous aortic valve degeneration with ECM substrate accumulation including periostin; TAILS identified shared and distinct ECM substrates/cleavage sites for each protease; TGFβ signaling was increased in mutant valves.\",\n      \"method\": \"Adamts7-/-Adamts12-/- double knockout mice, Doppler echocardiography, N-terminomics TAILS from secretome libraries, immunostaining, TGFβ pathway analysis\",\n      \"journal\": \"Journal of molecular and cellular cardiology plus\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in double KO with compensatory upregulation demonstrated, substrate identification by TAILS, in vivo functional cardiac phenotype\",\n      \"pmids\": [\"40115634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Cigarette smoke exposure upregulates vascular ADAMTS7 expression via CCL17/CCR4 signaling: cigarette smoke induces CCL17 in lungs and plasma; recombinant CCL17 upregulates ADAMTS7 in VSMCs; CCR4 silencing blocks this upregulation; conditioned media from CCL17-stimulated ADAMTS7-deficient VSMCs shows reduced inflammatory cytokine release by endothelial cells and reduced monocyte-to-EC adhesion; in Apoe-/- mice, smoking-induced plaque inflammation is blunted in Apoe-/-Adamts7-/- mice.\",\n      \"method\": \"Murine cigarette smoke exposure model, bulk RNA-seq of lung, recombinant CCL17 treatment of VSMCs, CCR4 siRNA knockdown, conditioned media EC activation assay, Apoe-/-Adamts7-/- double KO atherosclerosis model\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — preprint, multiple orthogonal methods including genetic KO epistasis and in vitro pathway validation, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The rs4887091 variant within the ADAMTS7 CAD GWAS locus alters a CTCF binding site and modulates function of a super chromatin interactome in coronary artery smooth muscle cells, linking the disease variant to ADAMTS7 gene regulation through 3D chromatin conformation.\",\n      \"method\": \"Single-nucleus gene expression and chromatin accessibility profiling (snRNA-seq + snATAC-seq) from 44 human coronary arteries, caQTL mapping, Hi-C chromatin conformation capture\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — preprint, computational/epigenomic mapping without direct functional validation of ADAMTS7 mechanism\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Pharmacological inhibition of ADAMTS7 with BAY-9835 improves left ventricular systolic function and reduces infarct size after AMI in mice; transcriptomic analysis identified the NF-κB/pyroptosis pathway as a downstream mechanism; BAY-9835 inhibits P65 phosphorylation and pyroptosis marker expression; NF-κB activation abolishes BAY-9835 protection.\",\n      \"method\": \"LAD ligation AMI mouse model, oxygen-glucose deprivation in AC16 cardiomyocytes, transcriptomic analysis, NF-κB pathway pharmacological activation/inhibition, echocardiography\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological inhibition with functional readout and transcriptomic mechanism, single lab, rescue experiment with NF-κB activator\",\n      \"pmids\": [\"42061659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In a high-fat diet mouse model, ADAMTS-7 promotes MMP-9 activation in cerebral vessels; ADAMTS-7 shRNA knockdown attenuates HFD-induced MMP-9 activity, reduced middle cerebral arterial diameter, and worsened neurological outcomes after MCAO; ADAMTS-7 is expressed in neurons, astrocytes, oligodendrocytes, and blood vessels in the brain.\",\n      \"method\": \"HFD mouse model, MCAO, lentiviral shRNA knockdown, Western blotting, immunostaining, cerebral vascular casting\",\n      \"journal\": \"CNS neuroscience & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — knockdown with functional readout establishing ADAMTS7→MMP-9 axis in brain vasculature, single lab, single method per endpoint\",\n      \"pmids\": [\"41968389\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADAMTS7 is a secreted zinc metalloprotease-proteoglycan that promotes vascular disease by degrading multiple extracellular matrix substrates—principally COMP (inhibiting VSMC migration and maintaining contractile phenotype), thrombospondin-1 (inhibiting re-endothelialization), LTBP4 (potentially affecting elastogenesis), TIMP-1 (disinhibiting MMP-9), and complement factor H (potentiating complement activation)—while in smooth muscle cells it also drives a non-proteolytic AP-1/PU.1/CD36 transcriptional axis that promotes foam cell formation; its prodomain is removed by furin at the cell surface, TIMP-4 is its primary endogenous inhibitor, and its expression is induced by TNF-α, PTHrP, IL-17A, and cigarette smoke-derived CCL17 via NF-κB and CCR4 signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADAMTS7 is a secreted, cell-surface-retained zinc metalloprotease-proteoglycan of the ADAM-TS family whose extracellular matrix proteolysis drives vascular disease, osteoarthritis, and ectopic tissue remodeling [#0, #4, #10]. The full-length protein (ADAMTS7B) is a chondroitin-sulfate-modified proteoglycan tethered near the cell surface through its ancillary and prodomains, and its catalytic activity requires furin-dependent multistep prodomain removal completed at the cell surface [#1]; a prodomain Ser-to-Pro variant (rs3825807) that impairs this maturation reduces substrate cleavage and is associated with protection from disease [#7]. ADAMTS7 cleaves an expanding set of matrix and regulatory substrates, including COMP/TSP-5 via its four C-terminal TSP motifs to promote VSMC migration and neointima formation [#2, #4], thrombospondin-1 to inhibit re-endothelialization and modulate angiogenesis [#9, #22], LTBP3/LTBP4 and EFEMP1/fibulin-3 [#11, #13], TIMP-1 to disinhibit MMP-9 and degrade plaque collagen [#15], and complement factor H to potentiate complement activation in renal injury [#16]. In hyperlipidemic mice, Adamts7 loss reduces atherosclerotic and neointimal lesions, and epistasis experiments establish COMP and TSP-1 degradation as the proteolytic basis of its proatherogenicity [#10, #14]; in smooth muscle cells it additionally drives foam cell formation through a non-proteolytic AP-1/PU.1/CD36 transcriptional axis that increases oxLDL uptake [#18]. In cartilage, ADAMTS7 is a PTHrP transcriptional target that inhibits chondrocyte differentiation and endochondral bone formation, acts as a GEP convertase, and forms a TNF-\\u03b1/NF-\\u03baB positive-feedback loop driving osteoarthritis [#5, #6, #8]. ADAMTS7 functions redundantly with ADAMTS12 to suppress heterotopic ossification and myxomatous valve degeneration [#17, #23]. TIMP-4 is its most potent endogenous inhibitor, and a structure-based selective small-molecule inhibitor (BAY-9835) has been developed against its catalytic domain [#20, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established ADAMTS7 as a new member of the ADAM-TS family, defining the multidomain architecture that would later explain its substrate targeting and cell-surface behavior.\",\n      \"evidence\": \"Primary structure determination and expression profiling during mouse embryogenesis\",\n      \"pmids\": [\"10464288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No enzymatic substrate identified\", \"No tissue function assigned\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolved how ADAMTS7 is processed and localized, showing it is a chondroitin-sulfate proteoglycan retained at the cell surface and activated by furin-dependent prodomain removal.\",\n      \"evidence\": \"Biochemical characterization, GAG analysis, furin inhibition and cleavage assays in HEK293F cells\",\n      \"pmids\": [\"15192113\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological ECM substrates beyond alpha-2-macroglobulin not yet defined\", \"In vivo relevance of cell-surface retention untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified COMP as the first matrix substrate and mapped the binding to ADAMTS7's C-terminal TSP motifs and COMP's EGF repeats, giving the protease a defined cartilage target.\",\n      \"evidence\": \"Yeast two-hybrid, GST pull-down, co-IP from native cartilage, in vitro digestion with domain mapping\",\n      \"pmids\": [\"16585064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequence of COMP cleavage unknown at this stage\", \"Did not address vascular roles\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected ADAMTS7 to both cartilage and vascular biology, showing PTHrP-driven inhibition of endochondral ossification via GEP inactivation and injury-induced COMP degradation that promotes VSMC migration.\",\n      \"evidence\": \"Transgenic and PTHrP-knockout mice, rat carotid balloon injury, overexpression/knockdown, GEP cleavage and substrate rescue assays\",\n      \"pmids\": [\"19487464\", \"19168437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether COMP is the sole relevant vascular substrate not yet resolved\", \"Endogenous regulation of ADAMTS7 activity incompletely defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined GEP as a competitive endogenous regulator that both binds ADAMTS7 and suppresses its TNF-\\u03b1-induced expression, establishing a layer of substrate-protective control.\",\n      \"evidence\": \"Yeast two-hybrid, GST pull-down, co-IP, immunofluorescence, in vitro digestion with domain mapping\",\n      \"pmids\": [\"20506400\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative importance of GEP versus other inhibitors in vivo unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked a CAD-associated coding variant to molecular mechanism, showing the rs3825807 prodomain Ser-to-Pro substitution impairs maturation and reduces COMP cleavage and VSMC migration.\",\n      \"evidence\": \"Genotype-stratified VSMC conditioned media, prodomain cleavage and migration assays\",\n      \"pmids\": [\"23415669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal in vivo link between variant and atherosclerosis not directly shown\", \"Effect on other substrates untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established a TNF-\\u03b1/NF-\\u03baB positive-feedback loop driving osteoarthritis, demonstrating cartilage-specific ADAMTS7 overexpression causes spontaneous OA-like disease.\",\n      \"evidence\": \"Cartilage-specific transgenic and knockdown mice, surgical OA model, NF-\\u03baB reporter assay\",\n      \"pmids\": [\"23928557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets downstream of ADAMTS7 in feedback loop not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided definitive in vivo genetic validation of ADAMTS7 as proatherogenic and dissected substrate-specific effects: TSP-1 degradation inhibits re-endothelialization while COMP loss is dispensable for that effect.\",\n      \"evidence\": \"Adamts7-/-, Tsp1-/-, and COMP-/- mice in wire injury and hyperlipidemic models, LC-MS/MS secretome, double-KO epistasis, proliferation assays\",\n      \"pmids\": [\"25712208\", \"25712206\", \"25921940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full substrate repertoire driving lesion formation not yet enumerated\", \"Cell-type origin of pathogenic ADAMTS7 unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Expanded the substrate landscape via unbiased N-terminomics, identifying LTBP3/LTBP4 cleavage, defining autolysis sites, and naming TIMP-4 the most potent endogenous inhibitor.\",\n      \"evidence\": \"TAILS proteomics of fibroblast secretome, N-terminal sequencing, in vitro cleavage with recombinant LTBP4, TIMP inhibitor panel\",\n      \"pmids\": [\"30926607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of LTBP cleavage on elastogenesis not directly tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Broadened the vascular substrate set with catalytic-dead-controlled proteomics, identifying 16 substrates including EFEMP1/fibulin-3 with a defined cleavage site.\",\n      \"evidence\": \"TAILS comparing WT vs E373Q ADAMTS7 in VSMCs and ECs, in vitro binary cleavage of purified EFEMP1\",\n      \"pmids\": [\"35283288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo phenotypic relevance of each new substrate not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated therapeutic and mechanistic proof by vaccination, showing anti-ADAMTS7 antibodies block COMP and TSP-1 degradation and reduce disease across models, confirming these substrates as the proatherogenic basis.\",\n      \"evidence\": \"Murine ligation, wire injury, ApoE-/- and LDLR-/- atherosclerosis, swine stent model, in vitro cleavage with vaccine-derived antibodies\",\n      \"pmids\": [\"36562301\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Durability and off-target effects of vaccination not addressed in timeline\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed two new pathogenic axes: TIMP-1 degradation that disinhibits MMP-9 and increases plaque collagen turnover, and complement factor H degradation that potentiates complement-driven renal injury.\",\n      \"evidence\": \"MS of plaques, co-IP, FRET PPI, in vitro degradation with MMP-9 readout; interactome, domain mapping, Adamts7-/- SLE/IR models with AAV-CFH rescue\",\n      \"pmids\": [\"37675562\", \"36735376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of TIMP-1 versus matrix substrates to plaque stability not quantified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a non-proteolytic transcriptional mechanism in which ADAMTS7 increases chromatin accessibility to drive an AP-1/PU.1/CD36 axis promoting SMC foam cell formation, and showed cell-type-specific transgenic but not knockout effects.\",\n      \"evidence\": \"SMC- and EC-specific conditional KO/transgenic mice, RNA-seq, ATAC-seq, oxLDL uptake assays, human carotid scRNA-seq\",\n      \"pmids\": [\"41609669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a secreted protease alters intracellular chromatin accessibility mechanistically unresolved\", \"Knockout failing to reduce disease versus prior whole-body KO data not reconciled in timeline\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Delivered the first structure-based selective inhibitor, using an ADAMTS7 catalytic-domain co-crystal to design BAY-9835 that exploits differences from MMP12.\",\n      \"evidence\": \"X-ray crystallography, homology modeling, medicinal chemistry, in vitro enzymatic inhibition\",\n      \"pmids\": [\"38348661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy not reported in this study\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided regulatory-genomic context for the CAD locus, linking rs4887091 to a CTCF site and 3D chromatin interactome controlling ADAMTS7 expression in coronary SMCs.\",\n      \"evidence\": \"snRNA-seq + snATAC-seq from human coronary arteries, caQTL, Hi-C (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct functional validation of the variant's effect on ADAMTS7\", \"Preprint, not peer reviewed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established functional redundancy with ADAMTS12 in cardiovascular and connective tissue, showing double-knockout-specific heterotopic ossification and myxomatous valve degeneration with substrate accumulation.\",\n      \"evidence\": \"Single and double Adamts7/Adamts12 KO mice, electron microscopy, SLRP measurements, echocardiography, TAILS, TGF\\u03b2 analysis\",\n      \"pmids\": [\"29618652\", \"40115634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of compensation between the two proteases not defined\", \"Direct substrate driving valve degeneration not pinpointed\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Extended ADAMTS7 induction and downstream pathology to new contexts: cigarette-smoke CCL17/CCR4 signaling upregulates vascular ADAMTS7, BAY-9835 protects the post-infarct heart via NF-\\u03baB/pyroptosis suppression, and ADAMTS7 promotes cerebral MMP-9 activation worsening stroke outcomes.\",\n      \"evidence\": \"Cigarette smoke and HFD mouse models, recombinant CCL17, CCR4 siRNA, LAD ligation and MCAO, BAY-9835 pharmacology, transcriptomics (one preprint)\",\n      \"pmids\": [\"42061659\", \"41968389\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CCL17/CCR4 result is a single-lab preprint awaiting peer review\", \"Direct substrate underlying cardioprotective and cerebral MMP-9 effects not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a secreted, cell-surface protease executes the non-proteolytic intracellular chromatin/AP-1/PU.1/CD36 program, and which specific substrate cleavages dominate each disease context, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism coupling extracellular ADAMTS7 to nuclear chromatin remodeling unknown\", \"Discordance between conditional-KO and whole-body-KO atherosclerosis phenotypes unexplained\", \"Hierarchy of substrate importance across vascular, renal, cardiac, and cerebral pathology undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 5, 9, 11, 13, 15, 16]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 2, 19]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 9, 11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [4, 17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [2, 4, 9, 11, 13, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 14, 16, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [16, 24]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 8, 17, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"COMP\", \"THBS1\", \"GRN\", \"TIMP4\", \"LTBP4\", \"EFEMP1\", \"TIMP1\", \"CFH\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}